作者
John K. Triantafillidis,El-Fellax Nadia,Florentia Fostira,Georgia I. Terzoudi,J. Fouskas,Stamatios Pinis
摘要
To the Editor: Although the etiology of inflammatory bowel disease (IBD) has not been fully elucidated, genetic studies have revealed certain susceptibility genes. The recently described genome-wide association has confirmed earlier findings related to the NOD2 gene and the IBD5 locus.1 Several associations between Crohn's disease (CD) and gene variants have been identified. Turner's syndrome (TS) is characterized by the partial or complete absence of 1 X chromosome (45,X karyotype).2 The situation is clinically manifested by short stature and ovarian dysgenesis leading to failure of secondary sexual development. Patients also have an increased risk for developing autoimmune diseases.3 X-chromosome abnormalities seem to play a significant role in the pathogenesis of IBD.4 Coexistence of CD and TS has rarely been described.5 We present here a patient with TS and autoimmune thyroiditis who developed severe CD at the age of 24. The patient responded well to the administration of biologic agents. The patient, a woman age 24, was transferred to our department from a district hospital in order to elucidate the cause and to confront intraabdominal abscesses accompanied by enteroabdominal fistulas. The disease started in May 2008 when she was admitted to the district hospital complaining mostly of moderate to severe abdominal pain, accompanied by fever and vomiting. With a possible diagnosis of acute appendicitis, an exploratory laparotomy and appendectomy were performed. In the next few weeks, 2 subsequent admissions to the same hospital because of persistence of abdominal pain, loss of weight, and fever failed to reach a firm diagnostic conclusion. The patient was transferred to our hospital for further investigation. At the age of 14 a diagnosis of TS was made based on the relevant clinical signs and chromosomal analysis. In 2001 a diagnosis of Hashimoto thyroiditis was made. It is worth mentioning that for almost 8 years she was receiving per os contraceptives. Thus, starting in August 2000 she was receiving estradiol 10 mg/d, and since February 2001 estradiol 10 mg/d plus progesterone 10 mg/d. In June 2001 she received microgynon 30 mg/d for 21 days. From June 2006 she was treated with mercilon 1 tab/d (ethinylestradiol 0.02 mg plus desogestrel 0.15 mg), thyrormon 1 tab/d, and from August 2006 until now T4 85 plus Mercilon. For the last 2 years she suffered from repeated episodes of otitis. She was a nonsmoker. Physical examination revealed short stature (height 136 cm) and weight (35 kg). No signs of hypothyroidism were seen. Hematological investigation showed parathormone 17.0 pg/mL (normal: 12–17), TSH 0.047 μIU/mL (0.27–4.2), F-T4 1.39 ng/dL (0.7–2.0), and antithyroglobulin Abs 585 IU/mL (negative or <115), anti-TPO 75.5 IU/mL (negative or <34). Other investigations included colonoscopy with ileoscopy, histology of the small and large bowel, small bowel barium follow-through, abdominal computed tomography, transdermal abdominal ultrasound on the right ileal fossa, and magnetic enteroclysis. The results of the previously mentioned studies were compatible with the diagnosis of CD of the small bowel accompanied by enteroabdominal fistulas. The chromosomal abnormality was confirmed by cytogenetic analysis (karyotype 45X0) (Fig. 1). During the diagnostic work-up the patient was receiving ciprofloxacine and metronidazole without significant clinical benefit. On the 16th day after admission administration of infliximab (5 mg/kg/day) was initiated. The clinical improvement of the patient was impressive. Almost in hours, both the abdominal pain and the general situation improved significantly. The drainage of fistulas was dramatically reduced. Improvement was continued after the second and third dose of the drug. Unfortunately, a severe allergic reaction was noticed during the fourth infusion of infliximab. Adalimumab (160 mg, 80 mg, and 40 mg every other week) was introduced with similarly good results. Six months after the introduction of treatment with biologic agents the patient is in a good clinical and physical situation. Photograph of chromosomal analysis of peripheral lymphocytes of the patient showing karyotype of 45XO. An increased incidence of autoimmune disorders as well as increased incidence of autoantibodies has been observed in patients with TS, the most common being autoimmune thyroiditis and IBD. Today, there is no doubt that a significant association of TS with CD certainly exists and the description of our patient in whom there was a combination of TS, CD, and autoimmune thyroiditis further emphasizes the role of genetic factors in the pathogenesis of the disease. It has been suggested that abnormalities in the X-chromosome may influence both genetic predisposition to autoimmune disorders and severity of inflammation. Recently, it was described that 1 of the human MHC-paralogs is located in the long arm of the X chromosome.4 It is of interest that Toll-like receptor 8 signaling, which enhances generation of proinflammatory cytokines, is located on the X chromosome.6 Thus, it is logical to suggest that further attention must be given to the role of the X-chromosome in the predisposition to IBD.7 Furthermore, hormonal imbalance with elevated FSH and LH levels in patients with TS could also contribute to the appearance of CD, as this hormonal imbalance could activate immunopathogenic mechanisms related to CD. Finally, the fact that the patient was receiving contraceptives, a well-known agent predisposing to the development of CD,8 for a long period of time must be taken into account concerning the appearance and natural course of CD in this unfortunate patient. In conclusion, screening of the gut for the possible existence of either subclinical CD or ulcerative colitis in patients with a firm diagnosis of TS is strongly recommended. Moreover, patients with TS should routinely be screened for the subclinical presence of autoimmune disorders, thus assuring early diagnosis and effective treatment. Administration of biologic agents as an induction or maintenance treatment results in fast and steady clinical improvement.